Pfizer

Investors are weighing Pfizer against Novo Nordisk as high-yield dividend picks. The comparison highlights Pfizer's larger yield against Novo Nordisk's stronger growth record in the obesity drug market, leaving income-focused investors to decide between a cheaper pharma stock and a faster-growing one. Analysts remain divided on which offers the better long-term payout.